Intracranial Metastases

Richards, Peter; McKissock, Wylie

doi:10.1136/bmj.1.5322.15

Cited by 137 publications

(28 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…[43][44][45][46][47] Although it is difficult to separate the relative contributions of the primary and metastatic disease, it is clear that achieving local control of the brain lesions is an important factor in prolonging survival. With the conventional treatment of fractionated whole brain radiation, there is a relatively high rate of local recurrence with a median survival of typically only 3-6 months 46,-50 and with associated intellectual and cognitive deterioration.…”

Section: Brain Metastasesmentioning

confidence: 99%

Serial evaluation of patients with brain tumors using volume MRI and 3D1H MRSI

Nelson¹,

Vigneron²,

Dillon³

1999

NMR Biomed.

159

View full text Add to dashboard Cite

Section: Brain Metastasesmentioning

confidence: 99%

Serial evaluation of patients with brain tumors using volume MRI and 3D1H MRSI

Nelson¹,

Vigneron²,

Dillon³

1999

NMR Biomed.

159

View full text Add to dashboard Cite

“…1 The therapeutic goal is to afford the patient the longest possible survival with minimal side effects and short hospitalization. Presently, surgery, irradiation, or chemotherapy used alone or in combi¬ nation25 are the three methods of treatment of potential benefit to those with metastatic brain tumors.…”

mentioning

confidence: 99%

Treatment for Patients With Cerebral Metastases

Markesbery¹,

Brooks²,

Gupta³

et al. 1978

Archives of Neurology

203

View full text Add to dashboard Cite

“…Ten percent of these patients have brain metastases at presentation, and 16-50% will develop symptomatic brain metastases within 1 year [1][2][3][4][5]. In general, the prognosis for these patients is poor, with a median survival of 1-2 months without treatment [6][7][8].…”

Section: Introductionmentioning

confidence: 98%

Gamma knife stereotactic radiosurgery for the management of incidentally-identified brain metastasis from non-small cell lung cancer

et al. 2011

View full text Add to dashboard Cite

Initial staging workup of non-small cell lung cancer (NSCLC) patients has led to increased identification of incidental brain metastases in patients who otherwise have minimal or no neurologic symptoms. We present our experience treating these metastases with stereotactic radiosurgery (SRS) alone and compare outcomes to those of patients with brain metastases treated with other strategies. We queried our neuro-oncology and radiation oncology databases for patients with incidentally-identified NSCLC brain metastases treated with upfront SRS alone between 1997 and 2006. We performed a retrospective analysis to evaluate outcomes in these patients. We found 26 patients with incidentally-identified NSCLC brain metastases (KPS 90-100) treated with SRS alone within 60 days of diagnosis of the metastases. These patients underwent SRS at a median 15 days from diagnosis to an average of 1.6 lesions (range: 1-7), with a mean lesion volume of 1.86 cm(3). The median prescription was 24 Gy delivered to the median 53% isodose line. The median survival for these patients was 8.2 months (mean 12.3 months) from diagnosis of brain metastases. Local CNS progression occurred in 2 patients (7.7%, mean 229.7 days). Survival was not statistically different from similar patients treated with whole brain radiotherapy (WBRT) (P = 0.98), WBRT + Surgery (P = 0.07) or WBRT + SRS (P = 0.62). Patients with incidentally-identified NSCLC brain metastases treated with SRS alone may achieve a survival rate comparable to patients managed with other standard therapeutic modalities. Our findings suggest that SRS alone may be a viable therapeutic option for patients with incidentally-discovered NSCLC brain metastases.

show abstract

Intracranial Metastases

Cited by 137 publications

References 6 publications

Serial evaluation of patients with brain tumors using volume MRI and 3D1H MRSI

Serial evaluation of patients with brain tumors using volume MRI and 3D1H MRSI

Treatment for Patients With Cerebral Metastases

Gamma knife stereotactic radiosurgery for the management of incidentally-identified brain metastasis from non-small cell lung cancer

Contact Info

Product

Resources

About